HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Sponsor: Tianjin Medical University Cancer Institute and Hospital
Study ID: NCT05864755
Phase: PHASE2
Status: Unknown

Conditions

Unrescetable Hepatocellular Carcinoma

Eligibility Criteria

Sex: ALL
Age: 18 Years - 85 Years
Healthy Volunteers: Not accepted

Interventions

HAIC+Durvalumab+Tremelimumab+Bevacizumab — DRUG
Tremelimumab：300mg, only once in cycle 1.Durvalumab: 1500mg, iv,q3w Bevacizumab: 15mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin

Study Details

To evaluate the efficacy and safety of HAIC combined with Durvalumab, Tremelimumab and Bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma

Key Dates

Start date: Jun 20, 2023
Status verified: May 2023
Primary completion: Dec 31, 2024
Completion: Dec 31, 2025

Study Design

Enrollment: 30 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: HAIC+Durvalumab+Tremelimumab+Bevacizumab

Primary Outcome Measure

Overall response rate ( ORR) per RECIST 1.1 [ Time Frame: Up to 1 year ]

Central Contacts

Huikai Li, MD
+8618622228639
[email protected]
Yang Liu, MD
+8617694950696